<DOC>
	<DOCNO>NCT00308139</DOCNO>
	<brief_summary>A Randomized , Open-Label , Multicenter , Comparator-Controlled Study Examine Effects Exenatide Long-Acting Release ( LAR ) Glucose Control ( HbA1c ) Safety Subjects Type 2 Diabetes Mellitus Managed Diet Modification Exercise and/or Oral Antidiabetic Medications .</brief_summary>
	<brief_title>Effects Exenatide Long-Acting Release Glucose Control Safety Subjects With Type 2 Diabetes Mellitus ( DURATION - 1 )</brief_title>
	<detailed_description>This trial design examine effect exenatide weekly compare exenatide twice daily glucose control safety subject least 30 week . The study also design examine glucose control transition exenatide twice daily 30 week exenatide weekly . Long-term safety efficacy monitor open-ended assessment period . This study conduct approximately 300 subject type 2 diabetes treat diet modification exercise alone combination stable regimen metformin , SU , thiazolidinedione ( TZD ) , combination metformin SU , combination metformin TZD , combination SU TZD .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Has type 2 diabetes mellitus treat diet modification exercise alone combination stable regimen combination metformin , sulphonylureas , thiazolidinediones minimum 2 month screen . Hemoglobin A1c ( HbA1c ) 7.1 % 11.0 % , inclusive , screen . Body mass index ( BMI ) 25 kg/m2 45 kg/m2 , inclusive , screen . ( For substudy ) Currently participate open end assessment period main study 2993 LAR105 Has previously expose exenatide ( ByettaÂ® ) , exenatide LAR , glucagonlike peptide1 ( GLP1 ) analog . Received investigational drug participate type clinical trial within 30 day prior screen . Has treat , currently treat , expect require undergo treatment follow excluded medication : Alpha glucosidase inhibitor meglitinide within 30 day screen ; Insulin within 2 week prior screen insulin longer 1 week within 3 month screen ; Regular use ( &gt; 14 day ) drug directly affect gastrointestinal motility ; Regular use ( &gt; 14 day ) systemic corticosteroid oral , intravenous , intramuscular route ; potent , inhale , intrapulmonary steroid know high rate systemic absorption ; Regular use ( &gt; 14 day ) medication addictive potential opiate opioids ; Prescription overthecounter weight loss medication within 6 month screen . ( For substudy ) Subjects terminate study participate dual chamber pen substudy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>long act release</keyword>
	<keyword>LAR</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>